

MolMed leads a project awarded a € 1.4 million grant by *Regione Lombardia* for optimisation of TK therapy manufacturing process

Milan (Italy), June 7, 2010 - MolMed S.p.A., a medical biotechnology company focused on the development of novel anticancer therapeutics, announces that the company is leader of a project that has been awarded a grant of € 1.4 million by *Regione Lombardia* for a € 2.2 million R&D project aimed at developing an innovative, automated manufacturing process for its cell-based therapy TK, that is currently in Phase III for high-risk leukaemias.

The project was submitted within a call of the plan by *Regione Lombardia* for the promotion of excellence in its industrial areas (known as *Metadistretti*). The grant is non-refundable and will partially cover R&D expenses of the project over a 36 month period. MolMed's partners in the project are Areta International S.r.l. and Datamed S.r.l.. MolMed will lead the project for the development of an automated closed system for the manufacturing of TK, which consists of patient-specific genetically engineered cells. Datamed will be responsible for design and optimisation of the system modules and related engineering work. Areta will contribute to the project by developing and implementing an optimised production and purification process for the monoclonal antibody used for the selection of engineered cells.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14.5.1999 as subsequently amended.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. MolMed's pipeline includes two novel therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III in high-risk acute leukaemias; NGR-hTNF, a novel vascular targeting agent (VTA), in Phase III for malignant pleural mesothelioma and in Phase II in five more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy.

For further information, please contact:

Holger Neecke
Director Business Development, Investor Relations
MolMed S.p.A.
phone: +39 02 21277.205
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com

Elena Lungagnani
Communication Manager
MolMed S.p.A.
phone: +39 02 21277.207
fax: +39 02 21277.325
e-mail: media.relations@molmed.com

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.